This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): female testosterone lotion, transdermal testosterone
Description: Androsorb uses micellar nanoparticles (MNP) technology to deliver testosterone through the skin when applied topically as an emulsion. MNPs are proprietary nano-structures that have been used to encapsulate and deliver drugs into the bloodstream. They are formulated in an emulsion that resembles and is applied to the skin like a lotion. MNPs facilitate transport of drug into superficial layers of the skin where a functional drug depot is created from which drug continues to diffuse into the systemic circulation.
Novavax and King
In June 2001, Novavax amended its exclusive worldwide licensingagreement with King Pharmaceuticals to include ANDROSORB. As part of the agreement, Novavax and King will co-promote ANDROSORB, onceapproved for licensure, in the U.S. and Puerto Rico, and King will haveexclusive marketing rights outside the U.S. and Puerto Rico for which Novavaxwill receive a royalty on sales.
Novavax and Esprit
In May 2006, Novavax announced it entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's micellar nanoparticle testosterone medicine.
Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from this new agreement will be...See full deal structure in Biomedtracker
Partners: Novavax, Inc.
Pink Sheet Novavax/Esprit Androsorb deal
Additional information available to subscribers only: